EYEN: eyenovia.com Company Value to Net Income

Corporate emblem and logo of Eyenovia Inc. (EYEN)

This Eyenovia, Inc. (EYEN) price chart with the -1.10 indicator reflects the dynamics of a company whose growth relies on the implementation of the Optejet system, the success of Mydcombi and Clobetasol, and trials to combat childhood myopia. The business develops robotic dispensers for precise, non-contact drug delivery to eliminate physician error. The startup is currently scaling sales across US centers and seeking strategic allies among pharmaceutical behemoths.

EYEN Eyenovia Inc.: Price to Earnings Ratio in the range 07/04/2022 - 07/03/2025

Analytical breakdowns for Eyenovia, Inc.

- price and consensus price forecast:
- market capitalization information:
Summary company analysis:EYEN (Eyenovia Corp)
Original product of eyenovia.com

The investment attractiveness of Eyenovia, Inc. (EYEN) is determined by the ratio of market capitalization to net income. By analyzing the P/E multiple, which stands at -1.10, an investor assesses the payback period and market expectations. This metric measures the cost of one dollar of profit, identifying whether the asset is overvalued or undervalued. For Eyenovia, Inc. (EYEN), this indicator reflects market confidence in the monetization of the Optejet platform. The integration of unique devices with pharmaceuticals creates a sustainable therapy standard, justifying future cash flows.